Vitrolife develops and supplies medical devices, culture media and equipment used in assisted reproduction and IVF clinics. Its portfolio supports the full laboratory workflow of fertility treatment, from gamete handling to embryo culture and cryopreservation. The company focuses on specialized reproductive-medicine customers rather than broad consumer healthcare.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 959 | — | 139 | 14.6% |
| Q1 2025 | 842 | — | 100 | -13.1% |
| Q2 2025 | 871 | — | 100 | -30.4% |
| Q4 2025 | 891 | -7.1% | -5,314 | -3,923% |
| Q1 2026 | 807 | -4.2% | 101 | 1% |
| Q2 2026 | 857 | -1.6% | 129 | 29% |
All markets — KeepWinning global stock screener
Other companies on Stockholm: SkiStar AB (publ) (SKIS B), Ratos AB (publ) (RATO B), Ratos AB (publ) (RATO A), Betsson AB (publ) (BETS B), Norion Bank AB (publ) (NORION), Creades AB (CRED A)